Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Accumulated Expenses data on file, last reported at $5.5 million in Q1 2026.

• Quarterly Accumulated Expenses fell 82.03% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (down 82.03% YoY) and the FY2025 annual result came in at $23.9 million, up 79.62% from the prior year.
• Accumulated Expenses eased to $5.5 million in Q1 2026, from $23.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $32.4 million in Q3 2024 to a low of $4.0 million in Q4 2022.
• A 5-year average of $15.0 million and a median of $9.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 85.1% — and 2023, when it soared 689.52%.
• Tracing ARCT's Accumulated Expenses over 5 years: stood at $4.0 million in 2022, then soared by 689.52% to $31.9 million in 2023, then tumbled by 58.27% to $13.3 million in 2024, then surged by 79.62% to $23.9 million in 2025, then sank by 77.02% to $5.5 million in 2026.
• The last three Accumulated Expenses figures came in at $5.5 million (Q1 2026), $23.9 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.